Publication
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerSolid Neoplasmcivic_curation1.00
- drugLarotrectinibcivic_curation1.00
- drugLarotrectinib Regimencivic_curation1.00
- geneNTRK1civic_curation1.00
- geneNTRK3civic_curation1.00
- variantNTRK1 Fusioncivic_curation1.00
- variantNTRK1 Fusioncivic_curation1.00
- variantNTRK3 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (10)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29466156
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NTRK1 Fusion3 | ||||||||
| Larotrectinib | Cholangiocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID6052In a Phase I/II study of Larotrectinib, highly selective TRK inhibitor, two patient with cholangiocarcinoma with NTRK fusion was enrolled. One of the two patient showed PR. PMID 29466156 · Drilon et al., 2018 · Open in CIViC | civic |
| 〃 | Malignant Pancreatic Neoplasm | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID6051In a Phase I/II study of Larotrectinib, highly selective TRK inhibitor, one patient with pancreatic cancer with NTRK fusion showed PR. PMID 29466156 · Drilon et al., 2018 · Open in CIViC | civic |
| 〃 | Solid NeoplasmCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID6567This was a Phase 1/2 study of 55 patients from 4 months to 76 years old with TRK-fusion positive tumors given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall re… (full text at CIViC) PMID 29466156 · Drilon et al., 2018 · Open in CIViC | civic |
| NTRK1 Fusion1 | ||||||||
| Larotrectinib Regimen | Solid NeoplasmCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11703This was a Phase 1/2 study in which 55 patients between 4 months and 76 years of age with TRK-fusion positive tumors were given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion type… (full text at CIViC) PMID 29466156 · Drilon et al., 2018 · Open in CIViC | civic |
| NTRK1 F589L + NTRK1 Fusion1 | ||||||||
| Larotrectinib | Solid NeoplasmCURATED_BROADER | Predictive | A | Supports Resistance | 2 | submitted | EID11542In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC) PMID 29466156 · Drilon et al., 2018 · Open in CIViC | civic |
| NTRK1 G595R + NTRK1 Fusion1 | ||||||||
| Larotrectinib | Solid NeoplasmCURATED_BROADER | Predictive | A | Supports Resistance | 3 | submitted | EID11540In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC) PMID 29466156 · Drilon et al., 2018 · Open in CIViC | civic |
| NTRK1 G667S + NTRK1 Fusion1 | ||||||||
| Larotrectinib | Solid NeoplasmCURATED_BROADER | Predictive | A | Supports Resistance | 2 | submitted | EID11543In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC) PMID 29466156 · Drilon et al., 2018 · Open in CIViC | civic |
| NTRK3 Fusion1 | ||||||||
| Larotrectinib | Solid NeoplasmCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID6568This was a Phase 1/2 study of 55 patients from 4 months to 76 years old with TRK-fusion positive tumors given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall re… (full text at CIViC) PMID 29466156 · Drilon et al., 2018 · Open in CIViC | civic |
| NTRK3 G623R + NTRK3 Fusion1 | ||||||||
| Larotrectinib | Solid NeoplasmCURATED_BROADER | Predictive | A | Supports Resistance | 3 | submitted | EID11541In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC) PMID 29466156 · Drilon et al., 2018 · Open in CIViC | civic |
| NTRK3 G696A + NTRK3 Fusion1 | ||||||||
| Larotrectinib | Solid NeoplasmCURATED_BROADER | Predictive | A | Supports Resistance | 2 | submitted | EID11544In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC) PMID 29466156 · Drilon et al., 2018 · Open in CIViC | civic |